| Literature DB >> 23169586 |
K Yamashita1, H Yatsuya, T Muramatsu, H Toyoshima, T Murohara, K Tamakoshi.
Abstract
BACKGROUND: Mechanisms underlying coffee's beneficial actions against cardiovascular disease and glucose metabolism are not well understood. Little information is available regarding association between coffee consumption and adipocytokines.Entities:
Year: 2012 PMID: 23169586 PMCID: PMC3347755 DOI: 10.1038/nutd.2012.6
Source DB: PubMed Journal: Nutr Diabetes ISSN: 2044-4052 Impact factor: 5.097
Figure 1Multiple mediation model with two mediators (M1, ln-adiponectin; M2, ln-leptin) in the context of this study. (1) Total effect of coffee consumption (X) on each marker (Y(s)) – path c. (2) Coffee consumption is hypothesized to exert indirect effects on each marker through ln-adiponectin (M1) and ln-leptin (M2), and to exert a direct effect on each marker (path c'(s)). The specific indirect effect of X on Y through M1 is defined by the product of the two paths linking X on Y through that mediator, that is, ab; similarly, the specific indirect effect of X on Y through M2 is defined by ab. The total indirect effect of X on Y is the sum of the two specific indirect effects, that is, ab + ab. The total effect of X on Y is thus the sum of the direct effect and all of the indirect effects: c = c' + ab + ab.
Baseline characteristics and multivariate-adjusted values of adipocytokines, inflammatory markers, lipids, glucose metabolism-related markers and liver enzymes according to daily coffee consumption, Aichi, 2002
| < | |||||
|---|---|---|---|---|---|
| Male (%) | 80 | 76 | 75 | 82 | 0.010 |
| Age (year) | 48.2±7.7 | 48.2±7.0 | 46.9±6.8 | 47.0±6.9 | <0.001 |
| Body mass index (kg m−2) | 22.8±2.7 | 22.9±2.7 | 22.8±2.7 | 22.6±2.6 | 0.51 |
| <0.001 | |||||
| Current smoking (%) | 20 | 26 | 34 | 50 | |
| Past smoking (%) | 22 | 22 | 21 | 18 | |
| Never (%) | 58 | 52 | 45 | 32 | |
| Alcohol intake (g per day) | 14.9±22.3 | 15.0±21.0 | 13.4±19.4 | 13.4±19.6 | 0.10 |
| Physical activity | 19 | 20 | 20 | 22 | 0.84 |
| Total energy intake (kcal per day) | 1918±600 | 1911±578 | 1975±577 | 2117±722 | <0.001 |
| Magnesium intake (mg per day) | 251±90 | 255±90 | 272±86 | 302±108 | <0.001 |
| Sugar use in coffee (%) | 22 | 16 | 15 | 10 | <0.001 |
| Green tea intake (⩾2 cups) (%) | 56 | 48 | 51 | 48 | 0.003 |
| eGFR (ml min−1 per 1.73 m2) | 76.2 (75.4–77.1) | 77.2 (76.2–78.2) | 77.4 (76.8–78.0) | 78.9 (77.5–80.3) | 0.033 |
| adiponectin (μg ml−1) | 6.58 (6.40–6.76) | 6.68 (6.48–6.88) | 6.92 (6.76–7.08) | 7.23 (6.84–7.65) | 0.005 |
| leptin (ng ml−1) | 4.69 (4.58–4.81) | 4.65 (4.53–4.78) | 4.50 (4.41–4.59) | 4.42 (4.20–4.64) | 0.27 |
| C-reactive protein (nmol l−1) | 4.10 (3.90–4.48) | 3.81 (3.52–4.10) | 3.52 (3.33–3.81) | 4.00 (3.43–4.57) | 0.014 |
| TNF-α (pg ml−1) | 12.25 (11.64–12.90) | 11.86 (11.25–12.50) | 12.05 (11.54–12.59) | 12.03 (10.89–13.29) | 0.85 |
| IL-6 (pg ml−1) | 1.75 (1.60–1.92) | 1.48 (1.34–1.63) | 1.56 (1.44–1.69) | 1.47 (1.22–1.76) | 0.070 |
| Total cholesterol (mmol l−1) | 5.33 (5.28–5.38) | 5.42 (5.36–5.48) | 5.42 (5.37–5.46) | 5.49 (5.38–5.60) | 0.025 |
| LDL cholesterol (mmol l−1) | 3.05 (3.01–3.10) | 3.14 (3.08–3.19) | 3.15 (3.12–3.20) | 3.21 (3.11–3.31) | 0.005 |
| HDL cholesterol (mmol l−1) | 1.52 (1.50–1.54) | 1.56 (1.54–1.59) | 1.56 (1.54–1.58) | 1.54 (1.49–1.58) | 0.012 |
| Triglycerides (mmol l−1) | 1.21 (1.17–1.25) | 1.15 (1.11–1.19) | 1.12 (1.09–1.15) | 1.17 (1.09–1.25) | 0.006 |
| Glucose (mmol l−1) | 5.05 (5.00–5.11) | 5.13 (5.07–5.18) | 5.05 (5.01–5.09) | 5.08 (4.97–5.18) | 0.16 |
| Insulin (pmol l−1) | 44.7 (42.8–46.8) | 46.2 (44.0–48.5) | 46.0 (44.3–47.7) | 46.0 (42.0–50.3) | 0.77 |
| HOMA-IR | 1.45 (1.38–1.52) | 1.52 (1.44–1.60) | 1.49 (1.43–1.55) | 1.49 (1.35–1.65) | 0.65 |
| AST (μkat l−1) | 0.375 (0.367–0.382) | 0.365 (0.358–0.373) | 0.357 (0.352–0.363) | 0.355 (0.340–0.368) | 0.004 |
| ALT (μkat l−1) | 0.326 (0.317–0.336) | 0.319 (0.309–0.329) | 0.309 (0.302–0.317) | 0.296 (0.277–0.312) | 0.007 |
| γ-GTP (μkat l−1) | 0.655 (0.630–0.680) | 0.632 (0.607–0.658) | 0.583 (0.565–0.603) | 0.582 (0.538–0.630) | < 0.001 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transferase; BMI, body mass index; CI, confidence interval; ; eGFR, estimated glomerular filtration rate; γ-GTP, γ-glutamyltransferase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment insulin resistant; hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin-6; TNF-α denotes tissue necrosis factor-α.
Values are percentage, mean±s.d. or geometric mean (95% CI).
Physical activity was defined as moderate and vigorous leisure-time physical activity 3 days or more and 60 min or more in total per week.
Differences in mean values were tested by one-way analysis of (co)variance, and differences in the proportions were tested by χ2-test.
Values were adjusted for age, BMI, smoking status, current smoking number, alcohol, physical activity, green tea intake, total energy intake, magnesium intake, green tea intake and eGFR.
n=199, 175, 265 and 52 from low to high intake in the analysis of TNF-α and IL-6.
linear trend tested using polynomial procedure was statistically significant (P<0.05).
Multivaria-adjusted associations of coffee consumption (continuous) with adipocytokines, inflammatory and glucose metabolism-related markers, lipids, and liver enzymes with or without further adjustment for adipocytokines, Aichi, 2002 (n=3317)
| P- | P- | P- | P- | |||||
|---|---|---|---|---|---|---|---|---|
| ln-adiponectin | 0.058 | < 0.001 | — | — | — | — | — | — |
| ln-leptin | −0.038 | < 0.001 | — | — | — | — | — | — |
| ln-hs-CRP | −0.039 | 0.026 | −0.022 | 0.20 | −0.132 | < 0.001 | 0.237 | < 0.001 |
| ln-TNF-α | −0.017 | 0.68 | −0.013 | 0.76 | −0.015 | < 0.001 | −0.013 | < 0.001 |
| ln-IL-6 | −0.057 | 0.16 | −0.049 | 0.23 | −0.052 | < 0.001 | −0.052 | < 0.001 |
| ln-TC | 0.042 | 0.019 | 0.051 | 0.004 | −0.016 | 0.42 | 0.207 | < 0.001 |
| ln-LDL-C | 0.055 | 0.002 | 0.066 | < 0.001 | −0.073 | < 0.001 | 0.172 | < 0.001 |
| ln-HDL-C | 0.025 | 0.11 | 0.006 | 0.69 | 0.318 | < 0.001 | −0.025 | 0.26 |
| ln-triglycerides | −0.039¶ | 0.018 | −0.015 | 0.34 | −0.259 | < 0.001 | 0.232 | < 0.001 |
| ln-Glucose | −0.009 | 0.59 | −0.004 | 0.81 | −0.066 | < 0.001 | 0.037 | 0.15 |
| ln-Insulin | 0.010 | 0.57 | 0.031 | 0.065 | −0.121 | < 0.001 | 0.357 | < 0.001 |
| ln-HOMA-IR | 0.007 | 0.69 | 0.027 | 0.11 | −0.124 | < 0.001 | 0.331 | < 0.001 |
| ln-AST | −0.064 | < 0.001 | −0.052 | 0.002 | −0.066 | < 0.001 | 0.219 | < 0.001 |
| ln-ALT | −0.059 | < 0.001 | −0.039 | 0.012 | −0.143 | < 0.001 | 0.302 | < 0.001 |
| ln-γ-GTP | −0.068 | < 0.001 | −0.051 | < 0.001 | −0.128 | < 0.001 | 0.249 | < 0.001 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transferase; γ-GTP, γ-glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment insulin resistant; hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin-6; LDL-C, low-density lipoprotein cholesterol; ln-, natural logarithmically transformed; TC, total cholesterol; TNF-α denotes tissue necrosis factor-α.
β denotes standardized regression coefficients.
Adjusted for sex, age, body mass index, smoking status, cigarettes smoked per day for current smokers, physical activity, total energy intake, intakes of alcohol, green tea and magnesium, sugar use in coffee, and log-transformed estimated glomerular filtration rate.
Model 2 adjusted additionally for ln-adiponectin and ln-leptin.
n=691 for the analyses of TNF-α and IL-6.
Path a(s),
Path b(s),
Path c(s),
Path c'(s) in multiple mediation analyses (see Figure 1).
Mediation role of adiponectin and leptin on the associations of coffee consumption with hs-CRP, triglycerides and liver enzymes, Aichi, 2002
| | |||||||
|---|---|---|---|---|---|---|---|
| ln-hs-CRP | −0.039 (−0.073, −0.005) | −0.017 (−0.025, −0.009) | 43.1 | −0.008 (−0.013, −0.004) | 19.7 | −0.009 (−0.016, −0.003) | 23.4 |
| ln-TC | 0.042 (0.002, 0.017) | −0.009 (−0.015, −0.004) | −21.4 | −0.001 (−0.005, 0.002) | −2.4 | −0.008 (−0.014, −0.004) | −19.0 |
| ln-LDL-C | 0.055 (0.008, 0.032) | −0.011 (−0.019, −0.006) | −20.0 | −0.004 (−0.008, −0.002) | −7.3 | −0.007 (−0.012, −0.002) | −12.7 |
| ln-triglycerides | −0.039 (−0.071, −0.006) | −0.024 (−0.035, −0.014) | 61.5 | −0.015 (−0.023, −0.007) | 38.7 | −0.009 (−0.015, −0.004) | 22.8 |
| ln-AST | −0.065 (−0.098, −0.032) | −0.012 (−0.019, −0.006) | 18.9 | −0.004 (−0.008, −0.001) | 5.9 | −0.008 (−0.014, −0.003) | 13.0 |
| ln-ALT | −0.059 (−0.092, −0.027) | −0.020 (−0.030, −0.011) | 33.5 | −0.008 (−0.013, −0.004) | 14.0 | −0.012 (−0.020, −0.005) | 19.5 |
| ln-γ-GTP | −0.068 (−0.098, −0.038) | −0.017 (−0.025, −0.009) | 25.2 | −0.007 (−0.012, −0.003) | 11.0 | −0.010 (−0.016, −0.004) | 14.1 |
Abbreviations: ALT, alanine transaminase; AST, aspartate transferase; CI, confidence interval; γ-GTP, γ-glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment insulin resistant; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; ln-, natural logarithmically transformed; TC, total cholesterol.
β denotes standardized regression coefficients
Calculated as proportion of the total indirect effects to the total effects of coffee consumption: for example, −0.017/(−0.039) × 100 for ln-hs-CRP. Negative values indicate that β for coffee consumption was strengthened by adjustment for ln-adiponectin and ln-leptin.